Advertisement

Topics

Search Results for "Sunitinib"

16:23 EDT 24th July 2016 | BioPortfolio

Matching Channels

None

Matching News

[News] Benefits of pazopanib over sunitinib for renal cell carcinoma

A post-hoc analysis of the findings of a randomised, open-label, phase 3 trial of two angiogenesis inhibitors for metastatic renal cell carcinoma has confirmed the overall clinical advantage of pazopa...

Sunitinib vs. Everolimus for Advanced Non–Clear-Cell Renal Cancer

Progression-free survival was longer with sunitinib in patients with papillary and unclassified histologies, but longer with everolimus in those with chromophobe histology.

Cabozantinib Improves PFS Over Sunitinib in Untreated Advanced RCC

A phase II trial found that cabozantinib offers significantly better progression-free survival over sunitinib in patients with untreated advanced RCC.

Exelixis’ Phase ll trial finds cabozantinib better than sunitinib in treating RCC

US-based biopharmaceutical company Exelixis has demonstrated improvement in progression-free survival (PFS) with cabozantinib, compared to sunitinib in patients with advanced intermediate or poor risk...

[Articles] Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

In patients with metastatic non-clear cell renal cell carcinoma, sunitinib improved progression-free survival compared with everolimus. Future trials of novel agents should account for heterogeneity i...

Sutent sunitinib: Phase III data

[Articles] Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Adjuvant treatment with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase 3 study. Furthermore, substantial treat...

Kidney cancer: Exosome transmission of sunitinib resistance

Matching PubMed Articles

Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.

Patients have responded well to the multi-targeted tyrosine kinase inhibitor (TKI) Sunitinib in the clinic. But the severe toxic side effects associated with Sunitinib limit its therapeutic index. To ...

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

To assess the efficacy and tolerability of sunitinib rechallenge in the third-line or later setting in patients with metastatic renal cell carcinoma (mRCC).

Sunitinib Induced Immune Thrombocytopenia.

Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and a...

Tyrosine kinase inhibitor sunitinib therapy is effective in treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival.

Bone metastasis from cancer of unknown primary (BMCUP) brings poor survival prognosis and its management remains controversial. Sunitinib (SUTENT) proved effective in many sorts of solid tumors but ha...

Sunitinib suppresses migration of ovarian cancer cells through negative modulation of TGF-β-mediated epithelial-mesenchymal transition.

Objective:To investigate the effect of sunitinib on the migration of ovarian cells and its mechanism of the negative regulation TGF-β mediated of epithelial-mesenchymal transition(EMT) by sunitinib t...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement